Delving into the Latest Updates on Servier Laboratories (Australia) Pty Ltd. with Synapse

概览

疾病领域	数量

血液及淋巴系统疾病	1
神经系统疾病	1
肿瘤	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

IDH1 x IDH2	1

关联

1

项与 Servier Laboratories (Australia) Pty Ltd. 相关的药物

Vorasidenib

靶点

IDH1 x IDH2

作用机制

IDH1抑制剂 [+1]

在研机构

Institut de Recherches Intern Servier [+6]

原研机构

Celgene Corp.

在研适应症

IDH1突变胶质瘤 [+13]

非在研适应症

急性髓性白血病 [+1]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2024-08-06

100 项与 Servier Laboratories (Australia) Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Servier Laboratories (Australia) Pty Ltd. 相关的专利（医药）

登录后查看更多信息

6

项与 Servier Laboratories (Australia) Pty Ltd. 相关的文献（医药）

2019-03-01·Heart, Lung and Circulation4区 · 医学

Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure

4区 · 医学

Article

作者: Adena, Michael A ; Sindone, Andrew P ; Hamann, Gary

BACKGROUNDIn the Systolic Heart failure treatment with the I_f inhibitor Trial (SHIFT) randomised placebo-controlled trial, ivabradine was shown to reduce hospital admissions for worsening heart failure (HF) and deaths due to HF in patients with symptomatic systolic HF and an elevated resting heart rate (HR). This analysis evaluates the cost effectiveness of adding ivabradine to optimal standard HF treatment in patients with a HR≥77 bpm.METHODSA Markov model was developed to assess the impact of ivabradine on mean survival and quality of life over a patient's lifetime (10 years). The hospitalisation and death rates were calculated using patient-level data from SHIFT. The reduction in quality of life due to HF hospitalisations was estimated directly from EQ-5D data collected in SHIFT. Australian costs were applied to the resource use from SHIFT.RESULTSThe modelled mean increase in survival with ivabradine was 0.115 years. The mean increase in quality-adjusted survival was 0.108 years. The average cost of ivabradine was A$2,957 and the cost savings associated with a reduction in HF hospitalisations was A$1,344. The cost per quality adjusted life year gained (QALYG) was A$14,905. The conservative approach to the modelled evaluation, as well as results of the sensitivity analysis, demonstrates that ivabradine is likely to be cost-effective in this indication.CONCLUSIONSThe conservative approach to the modelled evaluation, as well as results of the sensitivity analysis, demonstrates that ivabradine is a cost-effective treatment in the Australian setting for HF patients with a HR≥77 bpm on optimal standard therapy with a cost per QALYG similar or lower than that for other publicly funded treatments.

2013-02-01·Heart, Lung and Circulation4区 · 医学

In Patients with Chronic Stable Angina, Secondary Prevention Appears Better in the Very Old Compared to Younger Patients: The Coronary Artery Disease in gENeral practiCE (CADENCE) Substudy

4区 · 医学

Article

作者: Andrew J. Weekes ; Sharmalar Rajendran ; Claire Morgan ; Renuka Visvanathan ; Rosanna Tavella ; John F. Beltrame

BACKGROUNDWith our aging communities and the increased prevalence of coronary heart disease (CAD) with age, the impact of this disease in the very old warrants further investigation.OBJECTIVETo assess health outcomes and the attainment of guideline-based secondary prevention targets in the very old (>80 years, n=482) as compared to young (<65 years, n=582) and elderly (between 65 and 80 years, n=932) patients, all of whom had chronic stable angina.DESIGNThe coronary artery disease in general practice (CADENCE) study was a cluster-stratified cross-sectional survey. This study reports on health outcomes quantitated using the Seattle Angina Questionnaire and guideline targets achieved for blood pressure, smoking, lipids, diabetic control and body habitus.SETTINGS AND PARTICIPANTS2031 stable angina patients were recruited from 207 primary care practices.RESULTSDespite similar angina frequency scores, the very old were more physically impaired by their angina than both the young and elderly [76±25 (Young) vs. 70±26 (Elderly) vs. 63±28 (Very old), p<0.05 for both comparisons]. However, the very old had better quality of life scores than young stable angina patients [72±24 vs. 65±25, p<0.05] and were similar to the elderly [72±24 vs. 72±23, p>0.05]. Also blood pressure, lipid, diabetic and body habitus targets were more often achieved in the very old and elderly patients compared to young stable angina patients.CONCLUSIONDespite similar symptomatic status and greater physical limitations, the very old reported a better quality of life and more often achieved treatment targets than young stable angina patients. Failure to improve secondary prevention measures in younger age groups may potentially contribute to increased morbidity in older age, and failure to achieve 'Healthy Ageing'.

2012-12-01·International Journal of Stroke2区 · 医学

Disparities between Prescribing of Secondary Prevention Therapies for Stroke and Coronary Artery Disease in General Practice

2区 · 医学

Article

作者: Anderson, Craig ; Heeley, Emma ; Cass, Alan ; Weekes, Andrew ; Peiris, David ; Patel, Anushka ; Chalmers, John

Background Extensive evidence exists regarding the effectiveness of secondary prevention measures in patients with cardiovascular disease. Aim We aimed to examine the management and risk perceptions of cardiovascular events in people with established cardiovascular disease. Methods We analyzed data on 1453 patients, ≥55 year old, with a history of cardiovascular disease, from the Australian Hypertension and Absolute Risk Study. Results Compared with those 533 patients with stroke/transient ischemic attack, the 743 patients with coronary artery disease were twice as likely to have been prescribed secondary prevention therapies even after adjustment for potential confounding variables (adjusted relative risks 1·85; 95% confidence interval 1·56–2·19, 42% vs. 73% for use of the combination of blood pressure-lowering, lipid-lowering and antiplatelet therapies) and to have better control of lipid and blood pressure levels. General practitioners estimated that only 27% of patients with stroke/transient ischemic attack – 38% of those with coronary artery disease and 41% of those with both conditions – were at a high risk (≥15%) of a recurrent event. Patients similarly underestimated their risk of recurrent cardiovascular events, with only 8% of stroke/transient ischemic attack, 11% of coronary and 15% of combination disease patients rating themselves at ‘high’ or‘very-high’ risk. Conclusions This study reaffirms the large treatment gap in the uptake of secondary prevention for cardiovascular disease in primary care settings, being much greater for patients with cerebral compared with cardiac cardiovascular disease. This appears to be related to differential perceptions of cardiovascular risk across different vascular territories in both patients and doctors.

100 项与 Servier Laboratories (Australia) Pty Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Servier Laboratories (Australia) Pty Ltd. 相关的转化医学

登录后查看更多信息